Musi wa17 Kubvumbi, 2025, Hansoh Pharmaceutical yakazivisa kuti mushonga weB7-H3-targeted antibody-drug conjugate (ADC) HS-20093 weBoka wakazvigadzira wega wekubaiwa jekiseni wawana mvumo yekuverengerwa semushonga weBreakthrough-Therapy-Designated neNational Medical Products Administration (NMPA) yeChina, nechiratidzo chakakurudzirwa chekenza yemapapu isina squamous non-small cell cancer (NSCLC) isina kuchinja kwakatungamira, yakaenderera mberi kana kudzoka mushure me chemotherapy yakagadzirwa neplatinum.
HS-20093 iADC inoongororwa yeB7-H3 inoumbwa neantibody inorwisa B7-H3 monoclonal antibody inobatanidzwa netopoisomerase inhibitor (TOPOi) payload uye yakagadzirwa kurapa kenza yemapapu, sarcoma, kenza yemusoro nemutsipa nedzimwe bundu dzakasimba mumiedzo yakawanda yekiriniki muChina, nedanho repamusoro rekutsvagisa riri Phase Ⅲ clinical trials.
Kusarudzwa uku kunotsigirwa neruzivo rwekutanga rwekiriniki kubva muchidzidzo cheARTEMIS-001. Iyi iongororo iri kuenderera mberi yechikamu chekutanga chevarwere vanopfuura 300 vachiongorora kuchengetedzeka, kushivirira, uye kushanda kwekutanga kwekurwisa bundu mubundu rakasimba remunharaunda kana kuti remestatic (kenza yemapapu isina squamous isina squamous isina kuchinja kwemusana, yakaenderera mberi kana kudzoka mushure me chemotherapy yeplatinum), yakaitwa neHansoh Pharma.
Kare, HS-20093 yakawana mvumo yekubatanidzwa semushonga weBreakthrough-Therapy-Designated neNMPA nekuda kwezviratidzo zviviri:
·Kenza yemapapu ine masero madiki (ES-SCLC) yakatanga mushure mekurapwa kwekutanga (platinum doublet chemotherapy pamwe chete neimmuno-therapy).
·Osteosarcoma muvarwere vakamborapwa nenzira mbiri dzakamboshandiswa.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Email：myimmnet@163.com
Nguva yekutumira: Kubvumbi-22-2025